Last reviewed · How we verify
Varicella (Varilrix®)
Varicella vaccine induces immunity against varicella-zoster virus.
Varicella vaccine induces immunity against varicella-zoster virus. Used for Prevention of varicella (chickenpox).
At a glance
| Generic name | Varicella (Varilrix®) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by exposing the body to a weakened form of the virus, prompting an immune response that can help prevent future infections.
Approved indications
- Prevention of varicella (chickenpox)
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (PHASE3)
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (PHASE3)
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 (PHASE3)
- Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varicella (Varilrix®) CI brief — competitive landscape report
- Varicella (Varilrix®) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI